GlaxoSmithKline unveils $25 billion buyback - MarketWatch

LONDON (MarketWatch) -- GlaxoSmithKline on Wednesday took some of the attention away from disappointing sales of diabetes drugs by lifting its stock-buyback authorization to 12 billion …

CouponFollow Extension

$25
OFF

GlaxoSmithKline Unveils $25 Billion Buyback - MarketWatch

2 weeks from now

LONDON (MarketWatch) -- GlaxoSmithKline on Wednesday took some of the attention away from disappointing sales of diabetes drugs by lifting its stock-buyback authorization to 12 billion …

marketwatch.com

$2
OFF

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After …

2 weeks from now

3 days ago · GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that …

morningstar.com

14%
OFF

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion …

2 weeks from now

3 days ago · GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company announced a $2.5 billion share buyback plan.

benzinga.com

$2
OFF

GSK Launches $2.5 Billion Buyback, Lifts Sales Target After ... - MSN

2 weeks from now

By Yadarisa Shabong (Reuters) -GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales …

msn.com

4%
OFF

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook

2 weeks from now

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. ... GSK’s sales for the fourth quarter of 2024 rose 4% at constant ...

msn.com

$2
OFF

GSK Stock Jumps On Long-Term Outlook Boost, $2.5B Share …

2 weeks from now

3 days ago · GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of …

investopedia.com

$2
OFF

GSK Launches $2.5 Billion Buyback, Lifts Sales Target After Stellar ...

2 weeks from now

3 days ago · GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and …

reuters.com

$2
OFF

GSK Lifts Long-Term Outlook On Drug Pipeline, Buys Back Shares

2 weeks from now

3 days ago · (Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.Most Read from …

yahoo.com

83%
OFF

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After …

2 weeks from now

3 days ago · GSK GSK5.83%increase; green up pointing triangle plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The …

wsj.com

$25
OFF

Glaxo Doubles Buyback To $25 Billion As Earnings Flatten - CNBC

2 weeks from now

Jul 25, 2007 · GlaxoSmithKline more than doubled its share buyback programme to 12 billion pounds ($25billion) on Wednesday, boosting its shares even as sliding sales of diabetes drug …

cnbc.com

£2
OFF

GSK Launches £2bn Share Buyback And Upgrades Sales Forecast

2 weeks from now

3 days ago · Strong growth in HIV, oncology and specialty medicines have offset a 4 per cent decline in vaccine sales

thetimes.com

5%
OFF

GSK: Enters 2025 In Good Health, Launches £2bn Buyback

2 weeks from now

3 days ago · A £2bn share buyback programme has also been launched. GSK expects top line growth of 3-5% this year and an uplift in underlying operating profit of 6-8%. The shares were …

hl.co.uk

4%
OFF

Glaxo Delays Buyback As Profit Slips 4% - MarketWatch

2 weeks from now

GlaxoSmithKline on Wednesday reports a 4% profit fall for the second quarter as CEO Andrew Witty unveils his strategy to boost its vaccines and consumer...

marketwatch.com

$2
OFF

GSK Launches $2.5 Bln Buyback, Lifts Sales Target After Stellar Q4

2 weeks from now

3 days ago · GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and …

indiatimes.com

$2
OFF

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After …

2 weeks from now

3 days ago · The British pharmaceutical giant said Wednesday that the 2.0 billion-pound share buyback will be implemented over the next 18 months. The company said it now expects sales …

marketscreener.com

$2
OFF

GSK PLC ADR, GSK Quick Chart - (NYS) GSK, GSK PLC ADR Stock

2 weeks from now

Jan 13, 2025 · GSK - GSK PLC ADR Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts.com. ... GSK Launches $2.5 Billion Buyback, Raises …

marketwatch.com

FAQs about GlaxoSmithKline unveils $25 billion buyback - MarketWatch Coupon?

Will GSK increase its sales?

By Yadarisa Shabong (Reuters) -GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make up for pressures on its vaccines revenue. ...

Will GSK buy back £2 billion?

(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. Most Read from Bloomberg The British drugmaker boosted its 2031 sales forecast to over £40 billion, up from the more than £38 billion it previously expected. ...

Why did GlaxoSmithKline lose sales?

GlaxoSmithKline's sales decreased due to several products losing momentum; for instance, HIV drug Tivicay recorded quarterly sales of 426 million pounds, down 6% year-over-year, and another HIV drug, Triumeq, posted sales of 638 million pounds, down 8%. ...

Who owns GlaxoSmithKline?

The merger was completed in December that year, forming GlaxoSmithKline (GSK). The company's global headquarters are at GSK House, Brentford, London, officially opened in 2002 by then-Prime Minister Tony Blair. Andrew Witty took over as CEO in May 2008. ...

Does GlaxoSmithKline expect other products to help sales?

GlaxoSmithKline anticipates that other products will help sales from its biopharma business, which it expects to pick up in the coming quarters. The company currently has 39 products in development that are seeking new (or additional) indications. ...

Is GlaxoSmithKline going out of business?

GlaxoSmithKline has announced plans to close its antibiotics business at two UK sites with production shifting to Europe. This week, GSK agreed to sell rights to three antibiotic brands, including Zinnat, to Novartis’ Sandoz unit in a deal worth $500m. This is not indicative of the company going out of business, but rather a strategic move to streamline operations. ...